Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 1.00 |
| ▸ | ACACA | Q13085 | 14/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976549 | 1.00 | ACACB (1.00) | ACACBACACAMEN1KMT2AL3MBTL3 | |
| Hydrochloric Acid SCHEMBL6181697 | 0.99 | ACACB (0.98) | ACACBACACAMEN1KMT2AL3MBTL3 | |
| SCHEMBL6182670 | 0.96 | ACACB (0.93) | ACACBACACAMEN1KMT2AL3MBTL3 | |
| SCHEMBL977641 | 0.93 | ACACB (0.86) | ACACBACACACHRM3 | |
| SCHEMBL977639 | 0.93 | ACACB (0.86) | ACACBACACACHRM3 | |
| SCHEMBL6183505 | 0.92 | ACACB (0.84) | ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL976349 | 0.91 | ACACB (0.83) | ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL2622325 | 0.91 | ACACB (0.83) | ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL6181556 | 0.89 | ACACB (0.80) | ACACBACACA | |
| SCHEMBL6491415 | 0.88 | ACACB (0.78) | ACACBACACAL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150265-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | Neuera Pharmaceuticals, Inc. (US) | 2010-02-10 | — | — | EP | claimed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2581081-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2572712-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012139028-A2 | ANTI-VIRAL COMBINATION THERAPY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-10-11 | — | — | WO | disclosed |
| US-7884189-B2 | Acetyl-CoA carboxylase active domain for use as tool in designing antibiotic compounds, herbicide compounds, fungicide compounds; generating herbicide resistant plants; antidiabetic agents; antiobesity agents | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2150265-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | Neuera Pharmaceuticals, Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009023059-A2 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | ACACB 312/4885ACACA 702/4885MEN1 4221/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | ACACB 949/4885ACACA 1144/4885MEN1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.